Modern aspects of management tactics for women with genitourinary syndrome of menopause
- Authors: Pestrikova T.Y.1, Kotelnikova A.V.1,2,3, Veselkova E.G.1,3, Yurasova E.A.1, Yurasov I.V.1,2, Strelnikova N.V.1
-
Affiliations:
- Far Eastern State Medical University, Ministry of Health of Russia
- A.M. Voyno-Yasenetsky City Clinical Hospital
- "Dear Madleine" Multifunctional Medical Centre
- Issue: No 3 (2025)
- Pages: 169-176
- Section: Exchange of Experience
- URL: https://journals.eco-vector.com/0300-9092/article/view/679779
- DOI: https://doi.org/10.18565/aig.2025.11
- ID: 679779
Cite item
Open Access
Access granted
Abstract
Genitourinary syndrome of menopause is a chronic condition that occurs during the perimenopausal and menopausal periods. It is characterized by a wide range of symptoms and signs such as vaginal dryness, itching, burning, dyspareunia, bloody vaginal discharge, urinary disorders. These symptoms are caused by estrogen deficiency and tend to progress over time. Vulvovaginal atrophy and postmenopausal atrophic vaginitis are the most common manifestations.
Objective: To evaluate clinical, laboratory and instrumental parameters in postmenopausal women with atrophic vaginitis before and after topical application of estriol (50 µg/g).
Materials and methods: The study included 75 menopausal women with a verified diagnosis of postmenopausal atrophic vaginitis. The diagnosis was confirmed on the basis of the data obtained after clinical, laboratory and instrumental investigations. The monitoring of the patients included several visits where adequate topical therapy was administered and a number of follow-up examinations.
Results: The findings from the present study showed an improvement in clinical, laboratory and instrumental data of postmenopausal women with atrophic vaginitis during and after the treatment with ultra-low-dose estriol intravaginally (50 µg/g). There was a decrease in symptoms and clinical signs of vulvovaginal atrophy as well as normalization of vaginal microbiota in these women. The results of pelvic ultrasound obtained before, during and after the topical treatment with estriol showed neither an increase in M-echo of more than 5 mm, nor ovarian neoplasms or growth of myomatous nodes.
Conclusion: Intravaginal administration of ultra-low-dose estriol is considered to be a viable treatment option for women suffering from atrophic vaginitis.
Full Text
About the authors
Tatyana Yu. Pestrikova
Far Eastern State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: typ50@rambler.ru
ORCID iD: 0000-0002-1120-846X
Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology
Russian Federation, 680000, Khabarovsk, Muravyov-Amursky str., 35
Anastasia V. Kotelnikova
Far Eastern State Medical University, Ministry of Health of Russia; A.M. Voyno-Yasenetsky City Clinical Hospital; "Dear Madleine" Multifunctional Medical Centre
Email: tempo-m@mail.ru
ORCID iD: 0000-0002-8143-5932
PhD, Teaching Assistant at the Department of Obstetrics and Gynecology, Doctor at the Gynecological Department, Prof., Gynecologist
Russian Federation, 680000, Khabarovsk, Muravyov-Amursky str., 35; 680033, Khabarovsk, Tikhookeanskaya str., 213; 680000, Khabarovsk, Turgenev str., 49Elena G. Veselkova
Far Eastern State Medical University, Ministry of Health of Russia; "Dear Madleine" Multifunctional Medical Centre
Email: Dr.veselkova@inbox.ru
ORCID iD: 0009-0007-4339-6665
PhD student at the Department of Obstetrics and Gynecology, Gynecologist
Russian Federation, 680000, Khabarovsk, Muravyov-Amursky str., 35; 680000, Khabarovsk, Turgenev str., 49Elena A. Yurasova
Far Eastern State Medical University, Ministry of Health of Russia
Email: urasovaea@yandex.ru
ORCID iD: 0000-0002-7771-3549
Dr. Med. Sci., Professor, Department of Obstetrics and Gynecology
Russian Federation, 680000, Khabarovsk, Muravyov-Amursky str., 35Igor V. Yurasov
Far Eastern State Medical University, Ministry of Health of Russia; A.M. Voyno-Yasenetsky City Clinical Hospital
Email: urasovaea@yandex.ru
ORCID iD: 0000-0001-6397-7052
Dr. Med. Sci., Professor, Department of Obstetrics and Gynecology, Head of the Gynecological Department, Prof.
Russian Federation, 680000, Khabarovsk, Muravyov-Amursky str., 35; 680033, Khabarovsk, Tikhookeanskaya str., 213Natalia V. Strelnikova
Far Eastern State Medical University, Ministry of Health of Russia
Email: jpdom@mail.ru
ORCID iD: 0000-0002-1749-1323
PhD, Associate Professor, Department of Microbiology, Virology, Immunology
Russian Federation, 680000, Khabarovsk, Muravyov-Amursky str., 35References
- Прилепская В.Н. Генитоуринарный менопаузальный синдром: возможности эстриола. Гинекология. 2018; 20(1): 5-8. [Prilepskaya V.N. Genitourinary menopausal syndrome: the potential of estriol. Gynecology. 2018; 20(1): 5-8. (in Russian)]. https://dx.doi.org/10.26442/2079-5696_20.1.5-8.
- Прилепская В.Н., Ледина А.В. Эстриол (локальные и системные формы) в лечении атрофического вульвовагинита. Гинекология. 2015; 17(1): 66-8. [Prilepskaya V.N., Ledina A.V. Estriol (local and systemic forms) in the treatment of atrophic vulvovaginitis. Gynecology 2015; 17(1): 66-8. (in Russian)].
- Archer D.F., Kimble T.D., Lin F.D.Y., Battucci S., Sniukiene V., Liu J.H. A randomized, multicenter, double-blind, study to evaluate the safety and efficacy of estradiol vaginal gream 0.003% in postmenopausal women with vaginal dryness as the most bothersome symptom. J. Womens Health (Larchmt). 2018; 27(3): 231-7. https://dx.doi.org/10.1089/jwh.2017.6515.
- Lázaro-Carrasco de la Fuente J., Cuerva González M., González Rodríguez S., Delgado Marín J.L., Cuevas Castillo C., Nieto Magro C. Early effect of 0.005% estriol vaginal gel on symptoms and signs of vulvovaginal atrophy. J. Menopausal Med. 2022; 28(2): 60-9. https://dx.doi.org/10.6118/ jmm.21038.
- Дикке Г.Б., Гурская Т.Ю., Прокофьева С.В., Стольникова И.И., Андреева А.С., Репина Н.Б., Яговкина Н.В., Теплых С.В., Федорова Е.П. Эффективность и безопасность вагинального эстриола в ультранизкой дозе в терапии генитоуринарного менопаузального синдрома: многоцентровое рандомизированное контролируемое испытание III фазы. Акушерство и гинекология. 2022; 12: 146-56. [Dikke G.B., Gurskaya T.Yu., Prokofievа S.V., Stolnikova I.I., Andreeva A.S., Repina N.B., Yagovkina N.V., Teplykh S.V., Fedorova E.P. Efficacy and safety of ultra-low dose vaginal estriol in the therapy of genitourinary syndrome of menopause: a phase III multicenter randomized controlled trial. Obstetrics and Gynecology. 2022; (12): 146-56. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.303.
- Пестрикова Т.Ю., Котельникова А.В. Видовой состав вагинальной лактофлоры у женщин с заболеваниями влагалища и шейки матки. Женское здоровье и репродукция. 2021; 2(49): 16-25. [Pestrikova T.Yu., Kotelnikova A.V. Species composition of vaginal lactoflora in women with vaginal and cervical diseases. Women's Health and Reproduction. 2021; 2(49): 16-25. (in Russian)].
- Балан В.Е., Зароченцева Н.В., Чечнева М.А., Тихомирова Е.В., Кручинина Е.В., Титченко Ю.П., Годовалова О.С., Ловыгина Т.В., Джиджихия Л.К., Будыкина Т.С., Левкович Е.А., Овчинникова В.В., Царькова А.В. Оценка состояния вагинальной микробиоты у женщин с ГУМС в перименопаузе с учетом состояния эндотелия. Информационно‐методическое письмо. М: ООО «МАКС Пресс»; 2022. 20 с. [Balan V.E., Zarochentseva N.V., Chechneva M.A., Tikhomirova E.V., Kruchinina E.V., Titchenko Ju.P., Godovalova OS, Lovygina T.V., Dzhidzhikhia L.K., Budykina T.S., Levkovich E.A., Ovchinnikova V.V., Tsarkova A.V. Assessment of the state of the vaginal microbiota in women with GUMS in perimenopause, taking into account the state of the endothelium. Information and methodological letter. Moscow: MAKS Press LLC; 2022. 20 p. (in Russian)].
- Мартынов А.И., Демидова Т.Ю., Балан В.Е., Адашева Т.В., Тапильская Н.И., Москвичева Ю.Б., Кузнецова П.И., Балан П.В. Резолюция междисциплинарного экспертного совета «Управление метаболическим здоровьем как основа возраст-ассоциированных заболеваний. Фокус на активное долголетие». Терапия. 2022; 8: 114-9. [Martynov A.I., Demidova T.Yu., Balan V.E., Adasheva T.V., Tapilskaya N.I., Moskvicheva Yu.B., Kuznetsova P.I., Balan P.V. Resolution of the Interdisciplinary Expert Council «Management of metabolic health as the basis of age-related diseases. Focus on active longevity». Therapy. 2022; (8): 114-9. (in Russian)]. https://dx.doi.org/10.18565/therapy.2022.5.114-119.
- Stute P., Becker H.G., Bitzer J., Chatsiproios D., Luzuy F., von Wolff M. et al. Ultra-low dose - new approaches in menopausal hormone therapy. Climacteric. 2015; 18(2): 182-6. https://dx.doi.org/10.3109/13697137.2014.975198.
- Балан В.Е., Тихомирова Е.В., Журавель А.С., Титченко Ю.П., Ловыгина Т.В. Новые тенденции в современной менопаузальной гормональной терапии. Гинекология. 2021; 23(1): 33-6. [Balan V.E., Tikhomirova E.V., Zhuravel A.S., Titchenko Ju.P., Lovygina T.V. New trends in current menopausal hormone therapy. Gynecology. 2021; 23(1): 33-6. (in Russian)]. https://dx.doi.org/ 10.26442/20795696.2021.1.200635.
- Пестрикова Т.Ю., Швеева М.А., Юрасова Е.А. Психоэмоциональные нарушения в климактерическом периоде у женщин как фактор междисциплинарной проблемы (обзор литературы). Дальневосточный медицинский журнал. 2023; 3: 122-30. [Pestrikova T.Yu., Shveeva M.A., Yurasova E.A. Psycho-emotional disorders during female menopause as an interdisciplinary issue (literature review). Far Eastern Medical Journal. 2023; (3): 122-30. (in Russian)]. https://dx.doi.org/10.35177/1994-5191-2023-3-21.
- Инструкция по применению препарата «Блиссель». Доступно по: https://www.vidal.ru/drugs/blissel?ysclid=lsqxii8ymy695430531 [Instructions for use of the drug Blissel. Available at: https://www.vidal.ru/drugs/blissel?ysclid=lsqxii8ymy695430531 (in Russian)].
Supplementary files
